Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome

NCT00918411 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00918411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00918411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2009
Completion date
December 31, 2009
Enrollment
98 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome